SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Radiation Oncology Referral — Nelson Mandela

PatientNelson Mandela
Date of birth1943-07-18
IdentifiersMRN HR-ML021-SYN; SSN (made up) 000-21-6718
Document date2026-03-10
AuthorThandiwe Mokoena, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Reason for Referral

Man of 82 with newly diagnosed prostate adenocarcinoma, Grade Group 3, PSA 6.4 ng/mL, cT1c, NCCN unfavorable intermediate risk, found after a rising PSA on monitoring. Please advise on curative treatment, including radiotherapy with short-term androgen deprivation, and whether observation is reasonable at his age. [S]

Urgency: Routine, within four to six weeks. [S]

Questions for the consultant:

History of Present Illness

Fit and independent; walks every morning. Decades ago he had an operation that removed part of the prostate for benign enlargement with urinary blockage. Treated tuberculosis in the past, with no symptoms since. A rise in PSA on routine monitoring led to a multiparametric MRI (28 mL gland with a resection defect; 9 mm PI-RADS 4 lesion in the left peripheral zone; no extraprostatic extension) and an MRI-ultrasound fusion transperineal biopsy: Gleason 4+3 in 1 of 2 targeted cores (30 percent) and Gleason 3+4 in 2 of 12 systematic cores; 3 of 14 cores positive. Digital rectal examination: smooth, no nodule. PSA 6.4 ng/mL, testosterone 412 ng/dL, hemoglobin 14.1 g/dL, eGFR 69, alkaline phosphatase 74 U/L, A1c 5.5 percent, LDL 112 mg/dL, 25-hydroxyvitamin D 26 ng/mL. IPSS 7. PHQ-9 score 4. No regular medicines. PSMA PET/CT ordered; DXA booked for the day of the consultation [S]

Historical basis. These claims are historical evidence, not findings from a modern examination.

4 later historical claims are omitted because they describe events after the index age. See the teaching note.

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Problems

ProblemClinical statusVerificationCodeProvenance
Adenocarcinoma of the prostate, NCCN unfavorable intermediate risk: cT1c, Grade Group 3 (Gleason 4+3), PSA 6.4 ng/mL, 3 of 14 cores, found after a rising PSA; synthetic modern detail linked to his publicly announced prostate canceractiveconfirmed C61S — Synthetic grade, PSA, core count, stage, and risk group; the PSA rise, the biopsy-proven localized cancer that was not high grade, hormone therapy, and curative radiotherapy are from his doctors' and spokeswoman's public statements (D).
Hormone-sensitive prostate canceractiveconfirmed Z19.1S — Synthetic status in the modern episode.
History of pulmonary tuberculosis, treated, with no symptoms sinceresolvedconfirmed Z86.11S — The 1988 tuberculosis is documented (D); the coding and the statement that it has not recurred are synthetic.

Past Medical History

Historical biography with true dates. These events are not part of the synthetic care timeline.

Historical dateHistoryEvidence
1985Operation on the prostate for an enlarged gland causing urinary blockage, with part of the gland removed (type of operation not recorded in the cited sources)D (CLM-0003)
12 August 1988Tuberculosis, diagnosed after admission to hospital and treatedD (CLM-0004)
November 2000Raised PSA found on routine monitoring, followed by a prostate biopsyD (CLM-0005)

Family History

No family medical history is documented in the logged sources. Family history of real relatives is recorded only from documented or retrospective sources and is never synthesized.

Social History

Vital Signs

DateMeasureValueUnitProvenance
2026-03-10Body height183cmS
2026-03-10Body weight80.2kgS
2026-03-10Body mass index (BMI) [Ratio]23.9kg/m2S
2026-03-10Systolic blood pressure132mm[Hg]S
2026-03-10Diastolic blood pressure78mm[Hg]S
2026-03-10Heart rate68/minS
2026-03-10Respiratory rate14/minS
2026-03-10Body temperature36.6CelS
2026-03-10Oxygen saturation in Arterial blood by Pulse oximetry97%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-03-10Prostate specific Ag [Mass/volume] in Serum or Plasma6.4ng/mL<=4 ng/mLHighS
2026-03-10Testosterone [Mass/volume] in Serum or Plasma412ng/dL264 to 916 ng/dL in adult men; below 50 ng/dL is the castrate target on androgen deprivationNormalS
2026-03-10Hemoglobin [Mass/volume] in Blood14.1g/dL13.2-16.6 g/dLNormalS
2026-03-10Leukocytes [#/volume] in Blood by Automated count5.810*3/uL4-11 10*3/uLNormalS
2026-03-10Platelets [#/volume] in Blood by Automated count22610*3/uL150-400 10*3/uLNormalS
2026-03-10Sodium [Moles/volume] in Serum or Plasma140mmol/L135-145 mmol/LNormalS
2026-03-10Potassium [Moles/volume] in Serum or Plasma4.4mmol/L3.5-5.1 mmol/LNormalS
2026-03-10Glucose [Mass/volume] in Serum or Plasma94mg/dL70-99 mg/dLNormalS
2026-03-10Creatinine [Mass/volume] in Serum or Plasma1.08mg/dL0.74-1.35 mg/dLNormalS
2026-03-10Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M69mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
2026-03-10Calcium [Mass/volume] in Serum or Plasma9.4mg/dL8.6-10.3 mg/dLNormalS
2026-03-10Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma18U/L7-55 U/LNormalS
2026-03-10Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma74U/L40-129 U/LNormalS
2026-03-10Albumin [Mass/volume] in Serum or Plasma4.1g/dL3.5-5 g/dLNormalS
2026-03-10Hemoglobin A1c/Hemoglobin.total in Blood5.5%<=5.6%NormalS
2026-03-10Cholesterol [Mass/volume] in Serum or Plasma184mg/dL<=200 mg/dLNormalS
2026-03-10Cholesterol in HDL [Mass/volume] in Serum or Plasma52mg/dL>=40 mg/dLNormalS
2026-03-10Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation112mg/dL<=129 mg/dLNormalS
2026-03-10Triglyceride [Mass/volume] in Serum or Plasma98mg/dL<=149 mg/dLNormalS
2026-03-1025-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma26ng/mL30-100 ng/mLLowS
2026-03-10Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]4{score}S
2026-03-10International Prostate Symptom Score [IPSS]7{score}S

Assessment

Plan of Treatment